Neoadjuvant Treatment With the Combination of Vemurafenib and Cobimetinib in Limited Metastasis of Malignant Melanoma (AJCC Stage IIIC/IV) and Integrated Biomarker Study: a Single Armed Phase II Trial
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2017
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms NEO-VC
- 25 Oct 2017 Planned End Date changed from 1 Apr 2018 to 1 Apr 2020.
- 25 Oct 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2019.
- 10 Jun 2017 Biomarkers information updated